4.4 Article

Proline Oxidase (POX) as A Target for Cancer Therapy

Journal

CURRENT DRUG TARGETS
Volume 16, Issue 13, Pages 1464-1469

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138945011613151031150637

Keywords

Apoptosis; cancer; proline dehydrogenase (PRODH); proline oxidase (POX)

Funding

  1. NSC Poland [UMO-2014/13/B/NZ7/02196]
  2. Medical University of Bialystok as part of the OP DEP [POPW.01.03.00-20-008/09]

Ask authors/readers for more resources

Proline dehydrogenase/proline oxidase (PRODH/POX) is an enzyme catalyzing the first step of proline degradation, during which ROS and/or ATP is generated. POX is widely distributed in living organisms and is responsible for a number of regulatory processes such as redox homeostasis, osmotic adaptation, cell signaling and oxidative stress. Recent data provided evidence that POX plays an important role in carcinogenesis and tumor growth. POX may induce apoptosis in both intrinsic and extrinsic way. Due to ROS generation, POX may induce caspase-9 activity, which mediates mitochondrial apoptosis (intrinsic apoptosis pathway). POX can also stimulate TRAIL (tumor necrosis factor-related apoptosis inducing ligand) and DR5 (death receptor 5) expression, resulting in cleavage of procaspase-8 and thus extrinsic apoptotic pathway. However, this tumor suppressor in certain environmental conditions may act as a prosurvival factor. Genotoxic, inflammatory and metabolic stress may switch POX from tumor growth inhibiting to tumor growth supporting factor. The potential mechanisms which may regulate switching of POX mode are discussed in this review.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available